Sale disclosed
Bryan Supran
EVP, CLO and Secretary
Common Stock
- Reported value
- $398.86K
- Reported price
- $226.88 / share
Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…
ALNYLAM PHARMACEUTICALS, INC.
Last 30 daysNo qualifying insider buying. Sales: $398.86K by 1 insider.
Showing the first 6 of 20 trades on this page.
EVP, CLO and Secretary
Common Stock
Chief Executive Officer
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.
This score describes qualifying insider purchases at issuer level. Read the methodology
Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.
Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.
Director
Common Stock
The filing reports a zero transaction price. That is not a current market valuation; inspect the original filing for context.
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Common Stock
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Common Stock
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
Director
Stock Option (Right to Buy)
Derivative security · not the ordinary share price.
The filing reports a zero transaction price for this award. It does not mean the awarded securities have no market value.
| Reporting insider | Security / transaction | Amount / price | Value | Traded / disclosed | Source |
|---|---|---|---|---|---|
| EVP, CLO and Secretary | Common StockSale | 1,758$226.88 / share | $398.86K | Oct 2Filed Oct 6 · 4d later | SEC filing |
| Chief Executive Officer | Common StockGrant or award | 107Award · no purchase price | Non-cash award | Sep 19Filed Sep 22 · 3d later | SEC filing |
| Director | Common StockOption exercise or conversion10b5-1 | 3,830$0 reported · see filing | Not established | Jun 1Filed Jun 3 · 2d later | SEC filing |
| Director | Common StockSale10b5-15 trades | 3,830avg $299.18 / share | $1.15M | Jun 1Filed Jun 3 · 2d later | 5 filings
|
| Director | Stock Option (Right to Buy)Option exercise or conversion10b5-1 | Derivative units3,830$70.20 exercise / conversion price | Not a separate purchase | Jun 1Filed Jun 3 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units4,393Award · no purchase price | Non-cash award | Jun 1Filed Jun 3 · 2d later | SEC filing |
| Director | Common StockGrant or award | 671Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units1,441Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Common StockGrant or award | 838Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units1,802Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Common StockGrant or award | 671Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units1,441Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Common StockGrant or award | 671Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units1,441Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Common StockGrant or award | 671Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
| Director | Stock Option (Right to Buy)Grant or award | Derivative units1,441Award · no purchase price | Non-cash award | May 20Filed May 22 · 2d later | SEC filing |
Showing the latest 20 of 44 trades. Show all 44 trades
Alnylam Pharmaceuticals, Inc. - Common Stock · Stock
The filing reports a full sale for a spouse.
Cory A BookerReporting Senate member